Eli Lilly to invest $5B in Virginia plant amid Trump's pharma tariff threats

16.09.25 19:41 Uhr

Werte in diesem Artikel
Aktien

644,70 EUR -5,30 EUR -0,82%

Indizes

PKT PKT

17.986,3 PKT 78,6 PKT 0,44%

3.331,7 PKT 13,9 PKT 0,42%

6.688,5 PKT 27,3 PKT 0,41%

Eli Lilly on Tuesday announced a $5 billion investment in a manufacturing facility in Virginia as the pharmaceutical giant looks to expand its domestic production capacity amid the threat of tariffs.The manufacturing facility is expected to generate 650 high-wage jobs and 1,800 construction jobs at the West Creek Business Park in Goochland County, Virginia. The facility will produce active pharmaceutical ingredients for cancer, autoimmune and other advanced therapies.Eli Lilly's announcement represents an expansion beyond the original plan for a $2.1 billion facility that would've created 468 jobs."Our investment in Virginia underscores our commitment to U.S. innovation and manufacturing – creating high-quality jobs, strengthening communities, and advancing the health and well-being of Americans nationwide," said Lilly CEO David Ricks. "By expanding our domestic capacity, we're building a secure, resilient supply chain that delivers for patients today and supports the breakthrough medicines of tomorrow."TRUMP BRINGS KEY PRESCRIPTION DRUG HOME TO US IN SWEEPING WALMART DEALVirginia Gov. Glenn Youngkin said in a statement that "Lilly is one of the world's greatest innovators, and I want to thank them for this significant commitment to Virginia.""By expanding manufacturing capacity here in the United States, we are strengthening our economy, securing America's critical pharmaceutical supply chain, and positioning Virginia to lead in the industries that will drive innovation for generations to come."JOHNSON & JOHNSON INVESTING $2B IN US MANUFACTURING, CREATING NEW JOBSPharmaceutical companies have been stepping up their investment in U.S. manufacturing facilities amid President Donald Trump's efforts to push the industry to make more medicines domestically rather than importing them.Trump has threatened to impose tariffs on pharmaceutical products, saying he would start small and could raise them to as high as 250% to boost U.S. production.GET FOX BUSINESS ON THE GO BY CLICKING HEREEarlier this year, Eli Lilly outlined plans to spend at least $27 billion on four new U.S. manufacturing facilities to counter potential tariffs on drug imports.Reuters contributed to this report.Weiter zum vollständigen Artikel bei FOX Business

In eigener Sache

Übrigens: Eli Lilly und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Eli Lilly

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Eli Lilly

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: FOX Business

Nachrichten zu Eli Lilly

Wer­bung

Analysen zu Eli Lilly

DatumRatingAnalyst
20.12.2024Eli Lilly BuyJefferies & Company Inc.
31.10.2024Eli Lilly BuyJefferies & Company Inc.
13.02.2024Eli Lilly and BuyJefferies & Company Inc.
05.10.2018Eli Lilly and OutperformBMO Capital Markets
25.07.2018Eli Lilly and NeutralGoldman Sachs Group Inc.
DatumRatingAnalyst
20.12.2024Eli Lilly BuyJefferies & Company Inc.
31.10.2024Eli Lilly BuyJefferies & Company Inc.
13.02.2024Eli Lilly and BuyJefferies & Company Inc.
05.10.2018Eli Lilly and OutperformBMO Capital Markets
08.06.2018Eli Lilly and OverweightCantor Fitzgerald
DatumRatingAnalyst
25.07.2018Eli Lilly and NeutralGoldman Sachs Group Inc.
27.04.2017Eli Lilly and HoldArgus Research Company
20.03.2017Eli Lilly and NeutralUBS AG
22.07.2015Eli Lilly and Equal WeightBarclays Capital
08.01.2015Eli Lilly and HoldDeutsche Bank AG
DatumRatingAnalyst
21.04.2017Eli Lilly and UnderperformBMO Capital Markets
15.10.2012Eli Lilly and underperformJefferies & Company Inc.
30.06.2010Eli Lilly ErsteinschätzungSoleil Securities Group, Inc.
14.12.2009Eli Lilly sellGoldman Sachs Group Inc.
02.12.2009Eli Lilly sellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Eli Lilly nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen